MediWound Launches EscharEx® U.S. Clinical Development Program
MediWound Ltd. - Ordinary Shares (MDWD)
Last mediwound ltd. - ordinary shares earnings: 2/25 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.mediwound.com/press-releases
Company Research
Source: GlobeNewswire
Company’s primary focus turns to EscharEx following its successful collaboration for NexoBrid Company to initiate an adaptive comprehensive adequately controlled study in 4Q 2019 Company to host Analyst Day today, July 22, in New York, NY YAVNE, Israel, July 22, 2019 (GLOBE NEWSWIRE) -- MediWound Ltd. (the “Company”) (Nasdaq: MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and wound management, today announced its U.S. clinical development plan for EscharEx, the Company’s topical biological drug candidate for the debridement of chronic and hard-to-heal wounds. MediWound plans to initiate an adaptive comprehensive adequately controlled Phase 2 study in the fourth quarter of 2019 for second generation EscharEx. The study is designed to assess safety, efficacy and clinical benefit of EscharEx compared to placebo (gel vehicle) control and non-surgical standard of care (enzymatic and autolytic debridement) with a
Show less
Read more
Impact Snapshot
Event Time:
MDWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MDWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MDWD alerts
High impacting MediWound Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
MDWD
News
- MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025 [Yahoo! Finance]Yahoo! Finance
- MediWound to Host Virtual Key Opinion Leader Event to Discuss EscharEx® Phase III VALUE Study in Venous Leg Ulcers and Its Commercial Opportunity on January 8, 2025GlobeNewswire
- MediWound Ltd. (NASDAQ: MDWD) had its price target lowered by analysts at HC Wainwright from $28.00 to $25.00. They now have a "buy" rating on the stock.MarketBeat
- MediWound Ltd (MDWD) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]Yahoo! Finance
- MediWound (MDWD) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]Yahoo! Finance
MDWD
Earnings
- 11/26/24 - Miss
MDWD
Analyst Actions
- 10/11/24 - HC Wainwright
MDWD
Sec Filings
- 12/19/24 - Form 6-K
- 12/16/24 - Form 6-K
- 11/26/24 - Form 6-K
- MDWD's page on the SEC website